Legal regulation of gene editing procedure: USA and EU experience

The problem of legal regulation of gene editing in recent years has obviously become global in nature due to the lack of unified systematic legislation in the world. The authors set a goal to study the main existing regulatory legal acts and determine whether there is currently an array of legislati...

Full description

Bibliographic Details
Main Authors: Elena N. Trikoz, Diana M. Mustafina-Bredikhina, Elena E. Gulyaeva
Format: Article
Language:English
Published: Peoples’ Friendship University of Russia (RUDN University) 2021-12-01
Series:RUDN Journal of Law
Subjects:
Online Access:http://journals.rudn.ru/law/article/viewFile/26036/19205
id doaj-14d6ced1a85046c88f5fa0fc9865a076
record_format Article
spelling doaj-14d6ced1a85046c88f5fa0fc9865a0762021-03-26T15:00:26ZengPeoples’ Friendship University of Russia (RUDN University)RUDN Journal of Law2313-23372408-90012021-12-01251678610.22363/2313-2337-2021-25-1-67-8619898Legal regulation of gene editing procedure: USA and EU experienceElena N. Trikoz0Diana M. Mustafina-Bredikhina1Elena E. Gulyaeva2MGIMO University; Peoples' Friendship University of Russia (RUDN University)Peoples' Friendship University of Russia (RUDN University)Diplomatic Academy of the Ministry of Foreign Affairs of the Russian FederationThe problem of legal regulation of gene editing in recent years has obviously become global in nature due to the lack of unified systematic legislation in the world. The authors set a goal to study the main existing regulatory legal acts and determine whether there is currently an array of legislation that protects and at the same time establishes responsibility for the editors of the genome and persons who have given consent to it, before future generations, who will receive the edited gene, but who did not actually ask for it. The authors analyzed the most known general public cases related to patent disputes for the CRISPR-Cas9 genome editing technology and came to the conclusion that the strong desire to obtain the legal status of the author of the CRISPR/Cas9 genome modification technology is explained not by scientific ambitions but by commercial interest in a promising technology.http://journals.rudn.ru/law/article/viewFile/26036/19205human rightsinternational biolawlegal and ethical fieldsgenomegene editingbiomedical techniquespatent lawcrispr-cas9
collection DOAJ
language English
format Article
sources DOAJ
author Elena N. Trikoz
Diana M. Mustafina-Bredikhina
Elena E. Gulyaeva
spellingShingle Elena N. Trikoz
Diana M. Mustafina-Bredikhina
Elena E. Gulyaeva
Legal regulation of gene editing procedure: USA and EU experience
RUDN Journal of Law
human rights
international biolaw
legal and ethical fields
genome
gene editing
biomedical techniques
patent law
crispr-cas9
author_facet Elena N. Trikoz
Diana M. Mustafina-Bredikhina
Elena E. Gulyaeva
author_sort Elena N. Trikoz
title Legal regulation of gene editing procedure: USA and EU experience
title_short Legal regulation of gene editing procedure: USA and EU experience
title_full Legal regulation of gene editing procedure: USA and EU experience
title_fullStr Legal regulation of gene editing procedure: USA and EU experience
title_full_unstemmed Legal regulation of gene editing procedure: USA and EU experience
title_sort legal regulation of gene editing procedure: usa and eu experience
publisher Peoples’ Friendship University of Russia (RUDN University)
series RUDN Journal of Law
issn 2313-2337
2408-9001
publishDate 2021-12-01
description The problem of legal regulation of gene editing in recent years has obviously become global in nature due to the lack of unified systematic legislation in the world. The authors set a goal to study the main existing regulatory legal acts and determine whether there is currently an array of legislation that protects and at the same time establishes responsibility for the editors of the genome and persons who have given consent to it, before future generations, who will receive the edited gene, but who did not actually ask for it. The authors analyzed the most known general public cases related to patent disputes for the CRISPR-Cas9 genome editing technology and came to the conclusion that the strong desire to obtain the legal status of the author of the CRISPR/Cas9 genome modification technology is explained not by scientific ambitions but by commercial interest in a promising technology.
topic human rights
international biolaw
legal and ethical fields
genome
gene editing
biomedical techniques
patent law
crispr-cas9
url http://journals.rudn.ru/law/article/viewFile/26036/19205
work_keys_str_mv AT elenantrikoz legalregulationofgeneeditingprocedureusaandeuexperience
AT dianammustafinabredikhina legalregulationofgeneeditingprocedureusaandeuexperience
AT elenaegulyaeva legalregulationofgeneeditingprocedureusaandeuexperience
_version_ 1724201995574706176